Skip to main content
CTIS.
EU
Conditions
IMPs
Countries
Sponsors
Sites
Trial Map
Safety
Transparency
Landscape
EN — English
BG — Български
CS — Čeština
DA — Dansk
DE — Deutsch
EL — Ελληνικά
ES — Español
ET — Eesti
FI — Suomi
FR — Français
GA — Gaeilge
HR — Hrvatski
HU — Magyar
IT — Italiano
LT — Lietuvių
LV — Latviešu
MT — Malti
NL — Nederlands
PL — Polski
PT — Português
RO — Română
SK — Slovenčina
SL — Slovenščina
SV — Svenska
NO — Norsk
CTIS.
EU
✕
Conditions
IMPs
Countries
Sponsors
Sites
Trial Map
Safety
Transparency
Landscape
Notice
This is an independent non-profit initiative. We are not affiliated with the European Medicines Agency (EMA) or the official CTIS system. For the official EU Clinical Trials Information System, visit:
EMA Registry →
CTIS.eu
›
Conditions
› myelodysplastic syndrome (MDS); beta (β)-thalassemia (THAL); myelofibrosis (MF)
myelodysplastic syndrome (MDS); beta (β)-thalassemia (THAL); myelofibrosis (MF)
1 total trials
Filter these 1 trials by phase, country, sponsor and more.
Open in Search →
A phase 3B, open-label, single-arm, rollover study to evaluate long-term safety of Luspatercept in subjects who have participated in other L …
Recruitment ended
2022-502498-40-00
5
2019-07-26
Showing 1–1 of 1 trials